Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01514851
Recruitment Status : Completed
First Posted : January 23, 2012
Last Update Posted : June 8, 2012
Information provided by:

Brief Summary:
To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison with Calcium carbonate.

Condition or disease Intervention/treatment Phase
Hyperphosphatemia Drug: Lanthanum carbonate (BAY77-1931) Drug: Calcium carbonate Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 259 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis
Study Start Date : January 2006
Actual Primary Completion Date : May 2006
Actual Study Completion Date : May 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Arm Intervention/treatment
Experimental: Arm 1
750-2250mg/day, tid (three times a day), 8 weeks
Drug: Lanthanum carbonate (BAY77-1931)
Active Comparator: Arm 2
1500-4500mg/day, tid, 8 weeks
Drug: Calcium carbonate

Primary Outcome Measures :
  1. Change from baseline in pre-dialysis serum phosphate levels (PSPL) at the end of the double-blind period [ Time Frame: baseline to week 8 ]
  2. Presence/absence of incidence of hypercalcemia up to 8 weeks [ Time Frame: up to 8 weeks ]

Secondary Outcome Measures :
  1. Number of participants achieving target PSPL and time to achievement [ Time Frame: up to 8 weeks ]
  2. Serum calcium x phosphate product at the end of the double-blind treatment period [ Time Frame: Week 8 ]
  3. Serum intact-PTH (Parathyroid) levels [ Time Frame: Week 8 ]
  4. Serum calcium level corrected by serum albumin level at the end of the double-blind treatment period [ Time Frame: Week 8 ]
  5. Number of participants achieving the target serum calcium levels [ Time Frame: Week 8 ]
  6. Safety variables will be summarized using descriptive statistics based on adverse events collection [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pre-dialysis serum phosphate levels: ≧5.6 mg/dL and <11.0 mg/dL at 1 week after the initiation of the washout period.
  • Out-patient
  • Undergoing hemodialysis three times per week for at least previous 3 consecutive months

Exclusion Criteria:

  • Pre-dialysis serum phosphate levels of ≧10.0 mg/dL at the start of the washout period or ≧11.0 mg/dL at 1 week after
  • Corrected serum calcium level of <7.0 mg/dL or ≧11.0 mg/dL at the start of the washout period and/or 1 week after
  • Serum intact PTH (Parathyroid) of ≧1000 pg/mL at the start of the washout period
  • Pregnant woman, or lactating mother
  • Significant gastrointestinal disorders including known acute peptic ulcer
  • Liver dysfunction
  • History of cardiovascular or cerebrovascular diseases
  • Requiring treatment for hypothyroidism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01514851

Toyohashi, Aichi, Japan, 441-8023
Yatomi, Aichi, Japan, 498-0006
Asahi, Chiba, Japan, 289-2511
Kashiwa, Chiba, Japan, 277-0084
Matsudo, Chiba, Japan, 271-0077
Narita, Chiba, Japan, 286-0041
Kurume, Fukuoka, Japan, 830-8522
Kurume, Fukuoka, Japan, 830-8543
Isesaki, Gunma, Japan, 379-2211
Kobe, Hyogo, Japan, 658-0084
Mito, Ibaraki, Japan, 310-0844
Tsuchiura, Ibaraki, Japan, 300-0053
Takamatsu, Kagawa, Japan, 761-8024
Osaki, Miyagi, Japan, 989-6117
Sendai, Miyagi, Japan, 981-0912
Suita, Osaka, Japan, 564-0053
Fuji, Shizuoka, Japan, 417-0056
Hamamatsu, Shizuoka, Japan, 430-0903
Arakawa-ku, Tokyo, Japan, 116-0003
Kodaira, Tokyo, Japan, 187-0001
Nerima-ku, Tokyo, Japan, 176-0023
Shibuya-ku, Tokyo, Japan, 151-0053
Shinjyuku-ku, Tokyo, Japan, 160-0023
Chiba, Japan, 261-0011
Hiroshima, Japan, 730-0811
Kochi, Japan, 780-0066
Okayama, Japan, 701-0202
Saitama, Japan, 330-0854
Saitama, Japan, 330-0856
Saitama, Japan, 337-0043
Tokushima, Japan, 770-0011
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Head Medical Development Japan, Bayer Yakuhin Ltd. Identifier: NCT01514851     History of Changes
Other Study ID Numbers: 11877
First Posted: January 23, 2012    Key Record Dates
Last Update Posted: June 8, 2012
Last Verified: June 2012

Keywords provided by Bayer:
Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis

Additional relevant MeSH terms:
Phosphorus Metabolism Disorders
Metabolic Diseases
Calcium, Dietary
Calcium Carbonate
Bone Density Conservation Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents